Skip to main content

The U.S. Food and Drug Administration's Sentinel Initiative: Expanding the Horizons of Medical Product Safety

Basic Details
Date
Type
Publication
Description

This article describes 1) the impetus behind FDA’s efforts to identify and investigate postmarket safety signals related to regulated medical products, 2) Agency goals and activities in this area, and 3) the role of the Mini-Sentinel pilot in the development of their larger Sentinel Initiative.

Materials

Pharmacoepidemiology and Drug Safety, Volume 21, Issue Supplement S1, January 2012, Pages 9-11, DOI: 10.1002/pds.2311

Related Assessment(s)
PDS Supplement: The U.S. Food and Drug Administration's Mini-Sentinel Program
Author(s)

Melissa A. Robb RN; Judith A. Racoosin MD, MPH; Rachel E. Sherman MD, MPH, FACP; Thomas P. Gross MD; Robert Ball MD, MPH, ScM; Marsha E. Reichman PhD; Karen Midthun MD; Janet Woodcock MD, MPH

Corresponding Author

M. A. Robb, Office of Medical Policy, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave, Building 51, Room 6360, Silver Spring, MD 20993, USA. E-mail: Melissa.Robb@fda.hhs.gov